drugset
drugset / Trial / NCT04653467

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects

NCT04653467 ↗

Phase 1 Completed 88 enrolled Lakefront Biotherapeutics NV
RandomizedSequentialQuadruple-blindBasic science

Summary

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single (part 1) and multiple ascending (part 2) oral doses of GLPG4399, in adult, healthy, male subjects. In addition, the effect of food and the relative bioavailability (rBA) of GLPG4399, will be evaluated (part 3 and 4).

Timeline

Start
2020-11-06
Primary completion
2022-01-10
Completion
2022-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG4399 Unknown — Oral

Indications

No indication recorded.